share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/08/28 04:35

Moomoo AI 已提取核心信息

On August 22, 2024, Nukkleus received a notification from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Q2 2024 10-Q. This is the latest in a series of compliance issues, including failure to meet minimum bid price, market value of publicly held shares, and market value of listed securities requirements.Nukkleus has until October 21, 2024, to submit a compliance plan to Nasdaq. If accepted, the company may receive an extension until February 17, 2025, to file the Form 10-Q and regain compliance. The company is working to file the 10-Q and address other listing issues, but there's no assurance of success or additional extensions.Currently, this notification doesn't affect Nukkleus' listing on Nasdaq Global Market. However, failure to resolve these issues within prescribed timeframes could result in delisting, potentially impacting investor confidence and stock liquidity.
On August 22, 2024, Nukkleus received a notification from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Q2 2024 10-Q. This is the latest in a series of compliance issues, including failure to meet minimum bid price, market value of publicly held shares, and market value of listed securities requirements.Nukkleus has until October 21, 2024, to submit a compliance plan to Nasdaq. If accepted, the company may receive an extension until February 17, 2025, to file the Form 10-Q and regain compliance. The company is working to file the 10-Q and address other listing issues, but there's no assurance of success or additional extensions.Currently, this notification doesn't affect Nukkleus' listing on Nasdaq Global Market. However, failure to resolve these issues within prescribed timeframes could result in delisting, potentially impacting investor confidence and stock liquidity.
2024年8月22日,Nukkleus收到了纳斯达克的通知,表示因未及时提交2024年第二季度10-Q报告而不符合上市规则5250(c)(1)。这是一系列合规性问题中的最新一起,包括未能满足最低买盘价格、公开持股的市场价值以及上市证券的市场价值要求。Nukkleus必须在2024年10月21日之前向纳斯达克提交合规计划。如果获得接受,公司可能会被延长至2025年2月17日提交10-Q表格并恢复合规。公司正在努力提交10-Q并解决其他上市问题,但成功或额外延长的保证并不存在。目前,这份通知不影响Nukkleus在纳斯达克全球货币市场的上市。然而,未能在规定的时间内解决这些问题可能会导致退市,进而影响投资者信心和股票流动性。
2024年8月22日,Nukkleus收到了纳斯达克的通知,表示因未及时提交2024年第二季度10-Q报告而不符合上市规则5250(c)(1)。这是一系列合规性问题中的最新一起,包括未能满足最低买盘价格、公开持股的市场价值以及上市证券的市场价值要求。Nukkleus必须在2024年10月21日之前向纳斯达克提交合规计划。如果获得接受,公司可能会被延长至2025年2月17日提交10-Q表格并恢复合规。公司正在努力提交10-Q并解决其他上市问题,但成功或额外延长的保证并不存在。目前,这份通知不影响Nukkleus在纳斯达克全球货币市场的上市。然而,未能在规定的时间内解决这些问题可能会导致退市,进而影响投资者信心和股票流动性。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息